Sun Pharma Q4 Review – India Growth Partly Offset By Taro Decline: ICICI Direct

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Sun Pharmaceutical Industries Ltd.’s Q4 revenues grew 4.1% YoY to Rs 8523 crore (our estimate: Rs 8760 crore).

Indian formulations grew 12.9% YoY to Rs 2671 crore. U.S. formulations remained subdued at Rs 2695 crore, down 0.7% YoY.

Emerging markets business grew 3.5% YoY to Rs 1402 crore. The rest of the world markets business grew 6.3% YoY to Rs 1191 crore.

Active pharmaceutical ingredient segment de-grew 9.9% YoY to Rs 473 crore.

Ebitda margins expanded 738 basis points YoY to 24.0% (our estimates of 23.0%) mainly due to lower other expenditure and better gross margins.

Subsequently, Ebitda grew 50.3% YoY to Rs 2048 crore (our estimate: Rs 2015 crore).

Click on the attachment to read the full report:

ICICI Direct Sun Pharma Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button